AU2016290654C1 - Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts - Google Patents

Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts Download PDF

Info

Publication number
AU2016290654C1
AU2016290654C1 AU2016290654A AU2016290654A AU2016290654C1 AU 2016290654 C1 AU2016290654 C1 AU 2016290654C1 AU 2016290654 A AU2016290654 A AU 2016290654A AU 2016290654 A AU2016290654 A AU 2016290654A AU 2016290654 C1 AU2016290654 C1 AU 2016290654C1
Authority
AU
Australia
Prior art keywords
formula
compound
salt
crystalline form
side chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016290654A
Other languages
English (en)
Other versions
AU2016290654A2 (en
AU2016290654A1 (en
AU2016290654B2 (en
Inventor
Martin Bohlin
Chantal Devin
Sébastien Rocchi
Wei Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mimetogen Pharmaceuticals Inc
Original Assignee
Mimetogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mimetogen Pharmaceuticals Inc filed Critical Mimetogen Pharmaceuticals Inc
Publication of AU2016290654A1 publication Critical patent/AU2016290654A1/en
Publication of AU2016290654A2 publication Critical patent/AU2016290654A2/en
Application granted granted Critical
Publication of AU2016290654B2 publication Critical patent/AU2016290654B2/en
Publication of AU2016290654C1 publication Critical patent/AU2016290654C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016290654A 2015-07-09 2016-07-08 Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts Active AU2016290654C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190596P 2015-07-09 2015-07-09
US62/190,596 2015-07-09
PCT/EP2016/066281 WO2017005902A1 (en) 2015-07-09 2016-07-08 Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts

Publications (4)

Publication Number Publication Date
AU2016290654A1 AU2016290654A1 (en) 2018-01-25
AU2016290654A2 AU2016290654A2 (en) 2020-08-06
AU2016290654B2 AU2016290654B2 (en) 2021-07-08
AU2016290654C1 true AU2016290654C1 (en) 2021-11-11

Family

ID=56413639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016290654A Active AU2016290654C1 (en) 2015-07-09 2016-07-08 Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts

Country Status (8)

Country Link
US (4) US10125165B2 (enExample)
EP (2) EP3319978B1 (enExample)
JP (1) JP6801835B2 (enExample)
KR (1) KR102056257B1 (enExample)
CN (2) CN107849089B (enExample)
AU (1) AU2016290654C1 (enExample)
TW (1) TWI708779B (enExample)
WO (1) WO2017005902A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102056257B1 (ko) * 2015-07-09 2019-12-16 미메토젠 파르마슈티칼스 인크. 베타-턴 펩티도미메틱 사이클릭 염의 용액상 합성 및 결정화
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
KR102826649B1 (ko) * 2018-05-31 2025-06-30 쎄데르마 용액-상 펩티드의 합성 방법 및 그에 따른 보호 전략
US11427612B2 (en) * 2018-08-21 2022-08-30 Wayne State University Epimerization-free N to C solid-phase peptide synthesis
CN117279928A (zh) * 2021-05-07 2023-12-22 中外制药株式会社 包含n-取代氨基酸残基的环状化合物的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013191926A1 (en) * 2012-06-22 2013-12-27 Mimetogen Pharmaceuticals, Inc. Synthesis of beta-turn peptidomimetic cyclic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP254898A0 (en) * 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
HRP20041179B1 (hr) * 2002-06-11 2012-11-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
AU2009232352B2 (en) * 2008-04-04 2013-09-05 Mimetogen Pharmaceuticals Inc. Beta-turn peptidomimetic cyclic compounds for treating dry eye
AU2010217889B2 (en) * 2009-02-27 2014-12-18 Mimetogen Pharmaceuticals Inc. Peptidomimetic cyclic compounds for treating retinitis pigmentosa
EP2598604B1 (de) * 2010-07-29 2015-11-25 Merck Patent GmbH Flüssigkristallines medium enthaltend thiophenderivate
JP5710436B2 (ja) * 2011-09-26 2015-04-30 株式会社東芝 パターン形成方法
JP6516974B2 (ja) * 2013-06-14 2019-05-22 豊田合成株式会社 ゴム組成物及びゴム製品
CN105142777B (zh) * 2013-06-20 2017-12-26 埃克森美孚化学专利公司 长桥Salen催化剂
KR102056257B1 (ko) * 2015-07-09 2019-12-16 미메토젠 파르마슈티칼스 인크. 베타-턴 펩티도미메틱 사이클릭 염의 용액상 합성 및 결정화

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013191926A1 (en) * 2012-06-22 2013-12-27 Mimetogen Pharmaceuticals, Inc. Synthesis of beta-turn peptidomimetic cyclic compounds

Also Published As

Publication number Publication date
CN114874288A (zh) 2022-08-09
WO2017005902A1 (en) 2017-01-12
TWI708779B (zh) 2020-11-01
JP6801835B2 (ja) 2020-12-16
AU2016290654A2 (en) 2020-08-06
AU2016290654A1 (en) 2018-01-25
EP3319978C0 (en) 2025-02-19
EP4549450A2 (en) 2025-05-07
US20230357318A1 (en) 2023-11-09
US12281179B2 (en) 2025-04-22
CN107849089B (zh) 2022-07-05
US20170008923A1 (en) 2017-01-12
KR20180036982A (ko) 2018-04-10
US11078234B2 (en) 2021-08-03
TW201716425A (zh) 2017-05-16
AU2016290654B2 (en) 2021-07-08
CN107849089A (zh) 2018-03-27
US11753441B2 (en) 2023-09-12
HK1255355A1 (en) 2019-08-16
KR102056257B1 (ko) 2019-12-16
CA2991661A1 (en) 2017-01-12
EP3319978A1 (en) 2018-05-16
EP4549450A3 (en) 2025-07-02
US20190194251A1 (en) 2019-06-27
US20210300966A1 (en) 2021-09-30
US10125165B2 (en) 2018-11-13
EP3319978B1 (en) 2025-02-19
JP2018528928A (ja) 2018-10-04

Similar Documents

Publication Publication Date Title
US12281179B2 (en) Solution phase synthesis of β-turn peptidomimetic cyclic salts
TWI873263B (zh) 胜肽化合物的合成法
JP2025061589A (ja) 立体障害の大きなアミノ酸を含むペプチド化合物の製造方法
WO2023127869A1 (ja) Ｎ－アルキルアミノ酸、およびｎ－アルキルアミノ酸を含むペプチドの製造方法
NO139560B (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
US4638046A (en) Retro-inverso C-terminal hexapeptide analogues of substance P
DK151968B (da) Fremgangsmaade til fremstilling af pentapeptidet h-arg-x-asp-y-tyr-r ved oploesningssyntese
AU2007263805B2 (en) Pseudo proline dipeptides
CA2909584C (en) Synthesis of beta-turn peptidomimetic cyclic compounds
CA2991661C (en) Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
HK1255355B (en) Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
HK40081202A (en) Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
Balaev et al. Synthesis of leuprorelin acetate
RU2574392C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ТРИПЕПТИДА ОБЩЕЙ ФОРМУЛЫ (I) HPyr-His-TrpOH, ИСПОЛЬЗУЕМОГО В КАЧЕСТВЕ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ (1-3 ФРАГМЕНТА) В СИНТЕЗЕ СИНТЕТИЧЕСКИХ АГОНИСТОВ ГОНАДОТРОПИН-РИЛИЗИНГ-ГОРМОНА (LH-RH), МЕТОДОМ ЖИДКОФАЗНОГО ПЕПТИДНОГО СИНТЕЗА БЕЗ ПОСТАНОВКИ И СНЯТИЙ ЗАЩИТНЫХ ГРУПП
Chen et al. Facile Synthesis of Biologically Active Peptides Using Phase Transfer Reagents as C‐Terminal Protecting Group
EP3042911A1 (en) Method for producing dipeptide derivative containing disubstituted amino acid residue
CN118475590A (zh) N-烷基氨基酸以及包含n-烷基氨基酸的肽的制造方法
CN108864252A (zh) 制备nrx-1074的方法
DK149755B (da) Analogifremgangsmaade til fremstilling af lhrh-analoge nonapeptidamidderivater eller fysiologisk acceptable salte eller metalkomplekser deraf
PT1440977E (pt) Processo de síntese melhorado de derivados diamidas do tripéptido kpv

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ DEVIN, CHANTAL; TIAN, WEI; BOHLIN, MARTIN AND ROCCHI, SEBASTIEN

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 MAY 2020

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2021

FGA Letters patent sealed or granted (standard patent)